Clinical Trial: Universal STAR-T Cell Injection in R/R Autoimmune Diseases.

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07599280) titled 'Universal STAR-T Cell Injection in R/R Autoimmune Diseases.' on May 08.

Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.

This study evaluates the safety and efficacy of universal STAR-T cells in patients with R/R CTD-associated Immune Thrombocytopenia (CTD-ITP). Approximately 9 patients aged 18-65 will receive infusion of universal STAR-T cells at the starting dose of 3E6 STAR+T cells/kg. The main purpose of exploratory clinical research is to explore the efficacy and safety of universal STAR-T cell and the lymphodepletion regimen. The primary endpoint is observations of types, seve...